130 related articles for article (PubMed ID: 6605800)
41. Lymphocyte subpopulation in primary lung cancer.
Alsabti EA; Safo MH; Shaheen A
Oncology; 1979; 36(4):176-9. PubMed ID: 224357
[TBL] [Abstract][Full Text] [Related]
42. Effects of combined immunotherapy with levamisole and Bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy.
Olkowski ZL; McLaren JR; Skeen MJ
Cancer Treat Rep; 1978 Nov; 62(11):1651-61. PubMed ID: 310339
[TBL] [Abstract][Full Text] [Related]
43. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V
J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248
[TBL] [Abstract][Full Text] [Related]
44. Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells.
Avila-Moreno F; López-González JS; Galindo-Rodríguez G; Prado-García H; Bajaña S; Sánchez-Torres C
Cancer Immunol Immunother; 2006 May; 55(5):598-611. PubMed ID: 16133109
[TBL] [Abstract][Full Text] [Related]
45. Peripheral blood monocyte and T-lymphocyte activation levels at diagnosis predict long-term survival in head and neck squamous cell carcinoma patients.
Aarstad HJ; Vintermyr OK; Ulvestad E; Aarstad HH; Kross KW; Heimdal JH
APMIS; 2015 Apr; 123(4):305-14. PubMed ID: 25801083
[TBL] [Abstract][Full Text] [Related]
46. Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung.
Hanai N; Shitara K; Yoshida H
Cancer Res; 1986 Sep; 46(9):4438-43. PubMed ID: 3731100
[TBL] [Abstract][Full Text] [Related]
47. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
48. Microcytotoxicity assays of tumor immunity in patients with bronchogenic carcinoma correlated with clinical status.
Pierce GE; DeVald B
Cancer Res; 1975 Dec; 35(12):3577-84. PubMed ID: 1192421
[TBL] [Abstract][Full Text] [Related]
49. [Immunological index changes in the surgical treatment of lung cancer].
Kotliarov EV; Bekhtereva EI; Rask RE; Kriukova LI
Klin Khir (1962); 1981 Oct; (10):10-2. PubMed ID: 6975852
[No Abstract] [Full Text] [Related]
50. Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes.
Uchida A; Micksche M; Hoshino T
Cancer Immunol Immunother; 1984; 18(1):5-12. PubMed ID: 6333269
[TBL] [Abstract][Full Text] [Related]
51. Effects of interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma.
Hanagiri T; Yoshino I; Takenoyama M; So T; Fujie H; Imabayashi S; Eifuku R; Yoshimatsu T; Osaki T; Nakanishi R; Ichiyoshi Y; Nagashima A; Nomoto K; Yasumoto K
Jpn J Cancer Res; 1998 Feb; 89(2):192-8. PubMed ID: 9548447
[TBL] [Abstract][Full Text] [Related]
52. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis.
Wolf GT; Hudson JL; Peterson KA; Miller HL; McClatchey KD
Otolaryngol Head Neck Surg; 1986 Sep; 95(2):142-52. PubMed ID: 2954014
[TBL] [Abstract][Full Text] [Related]
53. Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.
Jiang L; Zhao Z; Jiang S; Lin Y; Yang H; Xie Z; Lin Y; Long H
Immunol Res; 2015 Jul; 62(3):316-24. PubMed ID: 25999209
[TBL] [Abstract][Full Text] [Related]
54. Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis in the tumoural region of adenocarcinoma as compared to squamous cell carcinoma of the lung.
Balabko L; Andreev K; Burmann N; Schubert M; Mathews M; Trufa DI; Reppert S; Rau T; Schicht M; Sirbu H; Hartmann A; Finotto S
Sci Rep; 2014 Dec; 4():7396. PubMed ID: 25491772
[TBL] [Abstract][Full Text] [Related]
55. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
Mizutani Y; Okada Y; Yoshida O; Bonavida B
Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
[TBL] [Abstract][Full Text] [Related]
56. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung.
Fujisawa T; Yamaguchi Y
Cancer; 1997 Feb; 79(3):474-81. PubMed ID: 9028357
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of tumor-induced lymphocyte blastogenesis by a factor or factors associated with peripheral leukocytes.
Hattler BG; Soehnlen B
Science; 1974 Jun; 184(4144):1374-5. PubMed ID: 4275320
[TBL] [Abstract][Full Text] [Related]
58. MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC).
Wang P; Vánky F; Klein E
Int J Cancer; 1992 Jul; 51(6):962-7. PubMed ID: 1386348
[TBL] [Abstract][Full Text] [Related]
59. [Immunological status in small cell and squamous cell lung cancer].
Janicka G; Przylipiak M; Chyczewska E; Kowal E
Pol Tyg Lek; 1983 Aug; 38(32):985-8. PubMed ID: 6320142
[No Abstract] [Full Text] [Related]
60. Demonstration of specific cell-mediated anti-tumor immunity in lung cancer to autologous tissue extracts.
Dean JH; Jerrells TR; Cannon GB; Kibrite A; Baumgardner B; Weese JL; Silva J; Herberman RB
Int J Cancer; 1978 Oct; 22(4):367-77. PubMed ID: 212376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
